Minapharm Pharmaceuticals on Sunday reported a 16.5% year-on-year rise in profits for the full fiscal year 2018.
The company’s net profits hit EGP 72.12 million from January to December 2018, against EGP 61.9 million a year earlier, according to a statement to the Egyptian Exchange (EGX).
Sales rose to EGP 1.43 billion last year, from EGP 1.23 billion in 2017, the Egypt-based drugmaker noted.
Minapharm Pharmaceuticals’s board of directors recommended distributing EGP 83 million as cash dividends for FY18, in addition to retained profits of 2017 results.
Dividends represent 67.5% of the firm’s paid-up capital.